Routine use of G-CSF support has been shown to substantially reduce myelosuppression in high-dose treatment of breast cancer patients receiving 250 mg m−2 paclitaxel, 90 mg m−2 doxorubicin and 3 mg m−2 cyclophosphamide (Hudis et al, 1995). Here, CSF3 is linked to breast carcinoma.